Autopsy report · NCT04160468

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

“The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 9 months before it stopped.
• 259 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

ContraFect

Sponsor type

Industry

Conditions

Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Endocarditis

Interventions

Exebacase; Placebo

Participants

259

Sites

55

Countries

United States

Trials that died the same way

• Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
  “DSMB stopped the study based on conclusion of likely futility of treatment on the primary outcome.” (83% match in meaning)
• Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
  “The DSMB recommended that the study be stopped as a result of concerns regarding safety and intolerability and insufficient evidence of efficacy.” (83% match in meaning)
• ATG Plus Low-dose PT-Cy for GVHD Prevention
  “DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” (81% match in meaning)
• A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
  “The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.” (81% match in meaning)
• Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
  “Recommendation by the DSMB that the study be stopped for futility” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.